The pharmaceutical giant Novartis AG (NVS.US) has finalized an agreement to acquire the UK-based biotechnology company Myricx Bio, in a deal potentially valued at up to $1.5 billion.
This strategic move adds an experimental anti-cancer drug to Novartis's portfolio, designed to deliver more potent therapeutic agents directly to tumor sites while minimizing damage to healthy cells.
According to a statement released by Novartis on Monday, Myricx shareholders will receive an upfront payment of $1.1 billion, along with potential milestone payments that could reach up to $400 million.
Myricx Bio is focused on developing a new generation of Antibody-Drug Conjugates (ADCs) and currently has two lead drug candidates targeting HER2-positive and B7-H3-positive tumors—proteins commonly expressed in various cancers, including breast and lung cancer.
This acquisition provides Novartis with a novel technology designed to kill cancer cells after the antibody reaches the tumor.
A core advantage of this technology is its ability to remain effective even after cancer cells develop resistance to the most widely used ADC therapies—a growing industry challenge as ADC drugs see increasing clinical application.
ADC drugs have become one of the hottest areas in oncology drug development, driving several multi-billion dollar licensing and M&A deals in recent years.
While Novartis had previously been a relative observer in this field, it has significantly ramped up its investment in the technology over the past two years.
However, the company's position in this area has lagged behind some of its peers.
CEO Vas Narasimhan acknowledged earlier in 2024: "We have a long history in ADC research, but we have not been successful. Part of our focused strategy is to examine areas where we believe we can build long-term, sustainable leadership."
Over the past two years, Novartis has demonstrably increased its commitment to ADC technology.
In October 2025, the company acquired Avidity Biosciences for $12 billion, marking the largest antibody-related transaction of that year.
CEO Vas Narasimhan has been steering a strategic transformation at Novartis, focusing on innovative drug development across core therapeutic areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology.
The acquisition of Myricx is a key step in deepening its commitment to the core oncology field and strengthening its ADC pipeline.
For Novartis, the value of the Myricx acquisition extends beyond the two lead candidates to the platform potential of the NMTi warhead technology itself.
Novartis has already demonstrated a successful "platform expansion" path in the field of Radioligand Therapy (RLT)—applying a core technology platform across multiple targets and indications.
With the Myricx acquisition, Novartis aims to replicate this logic: if the NMTi platform is validated clinically, it could be applied to a wider range of targets and tumor types.
From a financial perspective, Novartis boasts approximately $20 billion in free cash flow, providing ample capital flexibility for strategic acquisitions.
The $1.1 billion upfront payment is a manageable size for the company, while the potential $400 million in milestone payments ties the risk to later-stage clinical success, representing a value-creating bolt-on acquisition structure.
Comments